Hindustan Syringes shuts plant owing to pollution, triggers shortage scare

Disruption in the supply chain would result in shortage and other related issues like price increases

Hindustan Syringes and Medical Devices, HMD
IANS Chennai
2 min read Last Updated : Dec 11 2021 | 9:51 AM IST

The closure of needles and syringes manufacturing factories located in Haryana's Faridabad, adjoining Delhi, as a part of controlling emissions in the NCR will impact healthcare delivery across the country in general and the Covid-19 vaccination programme in particular, said a top official of Hindustan Syringes and Medical Devices Ltd (HMD).

"We have been asked to shut down our needles and syringes plants in Faridabad along with the factories of several other companies," HMD Managing Director Rajiv Nath told IANS.

"We daily produce 1.5 crore needles and 80 lakh syringes. This has come to a halt now. As we can't feed needles beyond two days buffer stock from Monday, other factories fed by the mother unit will be shut and daily 1.2 crore syringes will not be available nationally," he said.

According to him, syringes are already running short in India and globally and the government has put in export restrictions.

The expectation was that the export restriction will be lifted by December end as peak demand ebbed post Diwali, he added.

Nath, who is also the Forum Coordinator of Association of Indian Medical Devices Industry, in a letter to Prime Minister Narendra Modi, urged that syringes manufacturing facilities be declared as making products of national importance under the National Disaster Management Act.

He said the power supply from Haryana's power utility is stable and most of the company's gensets are powered by environmentally friendly piped natural gas.

Only small plants of HMD are connected to diesel gensets, Nath added.

He said HMD contributes over 66 per cent of India's syringes supplies for curative healthcare and immunisation.

Disruption in the supply chain would result in shortage and other related issues like price increases.

--IANS

vj/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusHindustan Syringes and Medical Devices LtdmedicalpollutionCoronavirus Tests

First Published: Dec 11 2021 | 9:48 AM IST

Next Story